ReviewFrontiers in public health2026
Pre-emptive pharmacogenetic testing in Italy: a review of evidence and multidisciplinary consensus on key priorities for implementation.
Review in Frontiers in public health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Pre-emptive pharmacogenetic (PGx) testing involves identifying genetic variants associated with drug response before prescribing medication, with the aim of guiding drug selection or dosing to reduce adverse reactions and improve outcomes. Despite decreasing costs and the growing feasibility of multi-gene panels, implementation of pre-emptive PGx testing remains limited in Italy. This study aimed to evaluate the potential impact of pre-emptive PGx testing in Italy and to identify barriers and strategies for its implementation. Methods: We conducted a review of current evidence and a multistage consultation process with Italian experts from pharmacology, laboratory medicine, genetics, clinical care, and public health. Results: Our analysis supports the clinical utility, economic sustainability, and feasibility of pre-emptive PGx testing. However, significant barriers persist, including limited real-world data, unclear reimbursement mechanisms, insufficient laboratory and IT infrastructure, inadequate clinician training, and patient concerns related to privacy and data protection. Conclusion: To enable broader implementation, strategic actions are needed across six areas: regulatory alignment, research investment, professional training and result interpretation, public awareness and consent, laboratory infrastructure, and IT systems and data governance.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.